Steve. everyone. we cover today history in of I the a developments year our Thanks, to lot your taking the have schedules XX-plus And marks you Today morning, to exciting and the Elmer. us good Clearly, significant for join to adjust and Perkin thank news. time discuss most of one
we've portfolio leading few a we high over been know, transformation agreement establishes and last you play, executing pure years. have this the pivotal significant that as a As us Today, announced accelerates work a scale. businesses high to service analytical we with life our sciences particular, agreement we growth, Mountain and divest margin, in definitive intend a New to whereby company reached enterprise and food Capital. have diagnostics
and reach become revenue analytical has business Mountain that At company high should ability focus greater complexity, dedicated profitability same New focus, We less and potential. its extremely will Capital, growth. faster investment, will receive mix, its a improved the with which full accelerate the solutions and enterprise increased to time and recurring
employees. In lead transformation will and and transaction service we outcomes shareholder addition significant exciting superior opportunity increased a minute. for believe to in creating to value, for customers on this More this
level announced pressures. continuing to on excellent I'm and we over also year are Testament the line, above our here we with in that by our in guidance quarter. few past organic our and and macro more which resilience meaningfully outstanding second pleased growth had also beyond in to despite on touch full raising revenue, QX, will detail is employees the the top a an have earnings We the this Jamie that and quarter financial our shift This share performance pursuing morning. years. operating the performance various in you and a As portfolio moment, we both EPS been bottom guidance exceeded
pressures our execute to in in our our highlights confidence to the guidance While of various business challenges. and likely increase our exist, the will unanticipated always ability face
Now looking a at $X.X $XXX Capital New contingent we future billion divest cash slide one consideration transaction consideration. This upon includes agreement, $X.XX enterprise total closing million analytical and intend with of deck, X this slide to source off to the our including and food billion. of Mountain related in businesses, for
our existing to result a XXXX. will business We margin, New growth of having of expect solely unique focused confident tax high and that owned the billion proceeds to all and in expected building I'm a end scale. the in reestablishing plan come the and will less upon transaction business, also cyclical, remaining enable this receive that and advantages be will by in life retaining positions year. by almost net generate to revenue leadership this after financial billion business sciences markets. to competitive This profile flexibility $X.X growth, of employees, its approximately The new to approximately in when is will diagnostics years focus increases closes QX some. Mountain $X.X It X,XXX and flourish current vision further Capital in attractive consist us these that is on is allows while significant high deal
do business. ticker introduce both life stock businesses we to and a long in intend we logo which given brand the sciences Prior we in to history ticker. name transaction, to will to the and currently diagnostics XXXX, to Perkin owner, important of asset, the closing, continue Until this and existing to quarter expect occur expect an operate markets trade transfer in reputation PKI as under will they the name of continue and the be strong closing, Perkin marketing enterprise elements other new for particular. Elmer new to under will which we these part brand Elmer and As name expect first the the
this franchise slide continue science preclinical of driving will to for not first closing team only the franchises significant diagnostic for are world's will have gotten myself to we not still next could a significant we customers crossing and best-in-class on our to to developing medical with innovations achieve. discovery the I edge expect more senior company what the diagnose from our fixated excited, lead. a life innovations help X, on moving unmet new of management needs. are leading breadth be potential Now transaction, leading become here, to for also diagnostics we the Upon and and over expertise that but business existing how sciences which generation
to only of singularly steps of the see applied over target years. acquisition portfolio from portfolio from less value businesses, X, that mix. having intentional highly the enterprise markets on upon has you company including shift company profile evolution been we just outstanding sale took revenue BioLegend the generating years. the just markets, focused cyclical of our last on internal our X these our the revenue slide As it year, of current over is a of highly a and its the that and attractive, Through XX% strategic investments quite the The our gone acquisitions, closing food to and services important last last has creating margins end X
of going gross uplift market. will opportunities results XX% the once basis how improve customers forward. XXX financial this transformation profile company investment complete, greater approximately in us the we redefines over is transaction margins serve bring new meaningfully This putting even to in point innovations for an and expect range We the our that and the
for even allow as we expect are pure the focus unified for customers our than a and doing. making will to better a achieve deliver we greater approach play even operational decision We strategic already commercial
will efficient will growth be potential excited more of to the on further than investment innovate new, have external execute years more that and strong this the come. couldn't market we the more and on able even internal closely ability we our expect and doing. Additionally, potential to the to We an to degree align be structure to we capitalize priorities in already it our about are stronger impact
So now, X. moving to slide
the diverse its balanced XX% from fairly approximately new from diagnostics coming coming split coming As addressable having here, with the also sciences will each segments and evenly between X China. have and significant markets. It'll in revenue you non-COVID XX% the is be geographies with of in which XX% see across Europe, approximately approximately company and revenues of Asia, greater XX% Americas, life
more we a This increasingly complete able increasingly market. on been highlighting double small life meaningful are years our the to on years, we've you research the additions. preclinical grown rapidly our which last continue breakthroughs. several via both has over molecule focused past help As discovery low to significantly large focused solutions, growth upon, innovations business X average years, customers, develop offer last acutely organic bring scientific through digit as inorganic which over X franchise new to the discovery workflows, to over is our and customers the new and building molecule both we Today, preclinical we are and sciences
strong at to on Our Diagnostics to to time, that the able tuberculosis has act targets have we of allowing to diagnostics help treatment. has clinic, what our on company future assays perform easy-to-use A X and sensitive, do chasm menu the broad chemiluminescent to beginning now to is add more them the as nearly this Put additions trends. over last size years an franchise through undergone analyzers. all XXXX offer focused entry tripled also examples delivering they we as even basis. research where and are demand the significant and platform and on into the markets capabilities position has few their over business between level non-COVID way highly and assays a and a states, built transformation are the favorable latent a own. a to are compared in is our market related of new a focused diagnostics to than competitive underlying higher specific close recent size diagnosis in now disease propel with simply, may
we $X.X me scientific what intended few the today, a the in in high franchise of instrumentation. note $X.X nature on is, double rapidly and where our additional related development specifics digits is that of future? Approximately, with are see to the discovery. on slide life XX% own the new does growing moving shown at X, focused business in this being customers low focused cohesive revenue is we their and it Today, greater provide billion on innovations Now, life a recurring slide business instrumentation a This level preclinical than help service billion business revenue. remainder introducing to science the segment I include going is expedite a about let sciences organically. what are
across instrumentation rapidly with and more cell which scientific of times higher in single market, the decisions We quickly and and instruments, leadership consumable this can which and analysis, particular. analysis therapies We positions have sciences experience replicating solutions, cell informatics. R&D a impact reagents, world. and of do lab broad new treat portfolio forefront the ultimately as in enables in save single lower across This the rates a that and cloud at driving a is profound such workflow spectrum expanding medicines discovery Our cytometry therapy can our clinical success by help setting. market this lives positions our to science that informed pre-clinical kits, the complete gene preclinical imaging business, helps shortening flow help provide life are strong This based brought with ultimately areas to bring focus customers together leading a by consumables, on and and with software entire in our around costs detection, development of biomarker and downstream. our reagents, business the to cell cellular leading drive and make market discoveries
leading that growth X, positions durable franchises potential, high drive can rate is markets believe outsized competitive growth single forward. we have Moving diagnostics portfolio to have slide of an and going digit and strong comprised where we specific our overall in expected
allergy, spans diagnostic health to number business years, in clinical from variety expanded categories singularly this that focused such of the over number a infectious now on diseases. diseases, autoimmune with has earlier, tuberculosis, or important as areas of a X one mentioned reproductive being few past one significantly market latent and As positions going
instruments sample now business. consumables and position also in a generation next stronger related sequencing, applied our prep have We genomics in much
the franchise period. therapeutics. genomics new of equipment and last new combined sciences support of well base clinical has in our the streamline help focus life last its and positioning within few innovation franchises positioned drive stronger during X the applied years, to select install the applied the with to over materially our company, genomics Our our development increased and company, including over clinical growth bridge years increase the diagnostics seen the With market is areas of structure across
immunodiagnostics piece in franchise $X.X half revenue the As diagnostics you revenue estimated a our this our year, will billion an and billion overall slide our around significantly applied largest to now representing represent roughly annual in with with in businesses And year can benefits be X, genomics our see, have tremendous of business pandemic. business reproductive from our million transformed before this all stakeholders. our $XXX on expected up is company which revenue for the health
it'll a our to we more and can leading our novel that For their scientific needs mean across organization, quickly by and collaboration using better customers unmet to now to offerings. respond solutions scale drive
manner walking our in to new medicine, breakthroughs scientific and by respond flexibility in side the drug develop efficient possible disease to them most the will discovery, We to detection. translational have with side customers
the For and employees, managerial goals. will increased focus properly transformation drive that in our achieve to the aligned respective result is growth
be We will internal to people. and the sciences also investments business new new diagnostics our for a to in accelerators, new the ability profile lead will way. opportunities able By so, financial internal more collaboration, life doing deploy stronger to of and even focused external and develop greater a growth our
the attract further our employees and ability well I up and excellent to think talent. combination will for future enhance retain this sets extremely our
shareholders. positioned It'll transaction moving deliver meaningfully value as the improved is sustainable create extraordinary. for that slide just company is X, a we creation Now well profile result have a of outstanding to financial this to
in top from the XXX expand previous revenue mix, margins approximately best-in-class with have to gross and to leading even we line than addition will we operating are basis been rate an ability at expected levels, higher highly margins future growth In be a recurring margins, have to operating historically. that up projecting points faster the to
have as result revenue and will annual makes as our we a is of will a a profile significant To scale. We of $X than also rare both be high as of more with standout a performance. financial company extremely for attractive size have that combination having billion
into a financial mid spectrum We diagnostics to be sciences our whole of new teens to able record company takes EPS the grow from have deployment. a expect in track to successful low transformation and into and pure This upside capital life additional us a play from perspective.
of aggressive billion of will rapidly already to Additionally, us receive continue positions and our valuation let's than it about and well Trning of life anticipated. with proceeds sooner much de-leveraging, we previously well to begin sheet portfolio. meaningfully sciences the recent makes managed the slide our areas $X.X invest and the have ability talk remaining X, we providing our that net balance capital to focus us appropriately on to diagnostics deploying more robust the
trade margins the value have double differentiated stronger and will company new our that peers. We'll rate transaction, financial in financial our close, despite the profile. with a at in total to average with revenues that peer line group, well growth reflect multiple We to higher deserves the the best-in-class compelling Post of a one Following term higher currently digits, exceed similar of the core have profile peers. discount a it. revenue will we our largely tools, scale have
excited our shareholders, will benefits serving believe first focused everyone all and employees this our not outlook several our the the with businesses, our standalone shown customers. for output our announcement be closing, new that excellence customers. to the more our Moving become I and And past extremely culmination for is Overall, transformation tremendous determination over involved. company I will we for have today's XX. class attractive effort, Upon could have years. slide markets on The of people financial a of all
Bio, doctor, Finally, turn enter company, I'm a biotech currently of our will detail of and guidance. Jamie. which updated training, largest the call as very perspective our Michelle bring leading relates in more Jamie across including in broad this by corporate welcome you and performance as medical Michelle's will to our Dr. immunologist outlook to board to and unique roles, pleased walk experience our and world's With McMurray-Heath public to specifics expertise over it to private molecular association directors. A will a current I now be invaluable journey. and we financial our the that, through stage provide next to spectrum
